Qiagen said it is working with Nvidia to integrate Nvidia BioNeMo and accelerated computing into Qiagen Digital Insights’ curated biomedical knowledgebases. The goal is to enable greater use of AI for target discovery, biomarker identification and disease-biology reasoning. The partnership will combine Qiagen’s Discovery Platform—which integrates genes, diseases, pathways, compounds and clinical insights—with graph-based AI and accelerated retrieval-and-reasoning workflows across knowledge graphs. Qiagen plans initial pilot programs for selected pharma and biotech partners, with broader availability after validation. Qiagen positioned the collaboration as a way to connect natural-language queries to structured scientific evidence while supporting multi-step, agentic drug-discovery workflows.